Why Trump’s Plan to Lower Drug Prices Has People Asking Questions
From Roll Call — Oct 24th, 2025
The Trump administration’s push to lower U.S. drug prices through direct deals with major pharmaceutical companies — including Pfizer, AstraZeneca, and EMD Serono — has drawn scrutiny over its transparency and impact.
“These are things they probably would have done anyway, or at least contemplated anyway,” said Spencer Perlman, managing partner and director of health research at Veda Partners. Perlman added that without full details, it’s unclear whether these “most-favored nation” arrangements will deliver meaningful savings for consumers or simply formalize existing plans.
Experts say the lack of visibility into the agreements makes it difficult to assess their true value — or whether they’ll meaningfully change U.S. drug pricing.
This excerpt and any accompanying media (including audio, video, or images) are shared under the principles of fair use, for informational and archival purposes only. All rights remain with the original publisher.